Market Overview

Morgan Stanley Speculates On Potential Abbott Laboratories Transaction

Share:
Related ABT
Jim Chanos, Kyle Bass Rip Oil And Pharma At SALT 2015
Earnings Beat Propels Abbott Laboratories To New All-Time High
Abbott Laboratories: The Future Is As Bright As The Past (Seeking Alpha)

In a report published Monday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating and $45.00 price target on Abbott Laboratories (NYSE: ABT).

In the report, Morgan Stanley noted, “Abbott is a unique healthcare asset, with high exposure to emerging markets and consumer- directed businesses, driving the potential for sustainable double digit earnings growth. Leverage opportunities are highly visible in both Nutritionals and Diagnostics, where peer margins demonstrate the potential for improvement. Expectations are low for the established pharma business, which has come under pressure in the developed markets and presents the potential for reacceleration as emerging market mix grows over time and austerity measures are lapped.”

Abbott Laboratories closed on Friday at $38.56.

Latest Ratings for ABT

DateFirmActionFromTo
May 2015JefferiesMaintainsHold
Apr 2015BarclaysMaintainsEqual-weight
Apr 2015JP MorganMaintainsNeutral

View More Analyst Ratings for ABT
View the Latest Analyst Ratings

Posted-In: David R. Lewis Morgan StanleyAnalyst Color Reiteration Analyst Ratings

 

Related Articles (ABT)

Around the Web, We're Loving...

Get Benzinga's Newsletters